Ivabradine plus conventional treatment vs conventional treatment alone in reducing the mean heart rate in heart transplant recipients: A randomized clinical trial

2021 ◽  
Author(s):  
Carolina Casadei Santos ◽  
Joao Manoel Rossi Neto ◽  
Marco Aurelio Finger ◽  
Ari Timerman ◽  
Carlos Contreras ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Heart Rate ◽  
Randomized Clinical Trial ◽  
Heart Transplant ◽  
Conventional Treatment ◽  
Transplant Recipients ◽  
The Mean ◽  
Heart Transplant Recipients ◽  
Mean Heart Rate

Enhanced brain natriuretic peptide response to peak exercise in heart transplant recipients

1998 ◽  
Vol 85 (6) ◽  
pp. 2270-2276 ◽  
Author(s):  
Bernard Geny ◽  
Anne Charloux ◽  
Eliane Lampert ◽  
Jean Lonsdorfer ◽  
Pascal Haberey ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Heart Transplantation ◽  
Left Ventricular Mass ◽  
Heart Transplant ◽  
Left Ventricular Mass Index ◽  
Left Ventricular ◽  
Peak Exercise ◽  
Transplant Recipients ◽  
Heart Transplant Recipients

We investigated the atrial (ANP) and brain natriuretic peptides (BNP), catecholamines, heart rate, and blood pressure responses to graded upright maximal cycling exercise of eight matched healthy subjects and cardiac-denervated heart transplant recipients (HTR). Baseline heart rate and diastolic blood pressure, together with ANP (15.2 ± 3.7 vs. 4.4 ± 0.8 pmol/l; P < 0.01) and BNP (14.3 ± 2.6 vs. 7.4 ± 0.6 pmol/l; P< 0.01), were elevated in HTR, but catecholamine levels were similar in both groups. Peak exercise O2uptake and heart rate were lower in HTR. Exercise-induced maximal ANP increase was similar in both groups (167 ± 34 vs. 216 ± 47%). Enhanced BNP increase was significant only in HTR (37 ± 8 vs. 16 ± 8%; P < 0.05). Similar norepinephrine but lower peak epinephrine levels were observed in HTR. ANP and heart rate changes from rest to 75% peak exercise were negatively correlated ( r = −0.76, P < 0.05), and BNP increase was correlated with left ventricular mass index ( r = 0.83, P < 0.01) after heart transplantation. Although ANP increase was not exaggerated, these data support the idea that the chronotropic limitation secondary to sinus node denervation might stimulate ANP release during early exercise in HTR. Furthermore, the BNP response to maximal exercise, which is related to the left ventricular mass index of HTR, is enhanced after heart transplantation.

scholarly journals Does cardiac transplant protect against broken hearts?

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A Isath ◽  
S Perembeti ◽  
A Correa ◽  
S Rao ◽  
A Chahal ◽  
...  
Keyword(s):  
Heart Transplant ◽  
Average Length ◽  
Myocardial Dysfunction ◽  
Case Reports ◽  
Fold Increase ◽  
Circulatory Support ◽  
Cardiac Transplant ◽  
Transplant Recipients ◽  
The Mean ◽  
Heart Transplant Recipients

Abstract Background Takotsubo cardiomyopathy (TC) is a reversible stress-induced myocardial dysfunction with increased sympathetic activity caused by excessive release of catecholamines playing a central role in its pathophysiology. The occurrence of TC in transplanted hearts is rare given the complete denervation done during transplantation. However, it has been demonstrated that 40% of transplant recipients undergo sympathetic re-innervation. There have only been case reports describing TC in post-transplant recipients. Purpose To evaluate the incidence, baseline characteristics and outcomes of TC occurring in heart transplant recipients using Healthcare Cost and Utilization Project (HCUP) National (nationwide) Inpatient Sample (NIS) in United States from 2009 to 2014. Methods Using NIS data, we identified patients who underwent cardiac transplantation using ICD9 procedure codes 37.5 and 33.6. Among these patients, we identified those admitted to the hospital with diagnosis of TC based on ICD-9-CM code 429.83. We presented categorical data as percentages and continuous data as mean or median as appropriate. Results We identified 257 hospitalizations for TC in heart transplant recipient patients. There was an approximately 9-fold increase in admissions from 11 in 2009 to 95 in 2014. Among patients with TC, the mean age was 65.3±1.8 years and majority were female (76.6%). A majority of patients were Caucasians (63%) followed by smaller proportion of African-Americans (13.2%). In-patient mortality in patients admitted with TC following heart transplant was 11.3% (n=29). During the hospitalization, 4.8% of patients had cardiogenic shock and 2.8% required mechanical circulatory support. The average length of stay for patients with TC was 16.6±3.3 days. The mean cost of hospitalization for these patients when adjusted for inflation were 237248±55709 dollars. Conclusion TC can still occur in substantially in heart transplant recipients and should be considered one of the differential diagnosis in transplant patients presenting to the hospital. Funding Acknowledgement Type of funding source: None

Age-related heart rate response to exercise in heart transplant recipients. Functional significance

2002 ◽  
Vol 443 (5) ◽  
pp. 698-706 ◽  
Author(s):  
Claudio Marconi ◽  
Mauro Marzorati ◽  
Roberto Fiocchi ◽  
Filippo Mamprin ◽  
Paolo Ferrazzi ◽  
...  
Keyword(s):  
Heart Rate ◽  
Heart Transplant ◽  
Functional Significance ◽  
Heart Rate Response ◽  
Transplant Recipients ◽  
Age Related ◽  
Heart Transplant Recipients ◽  
Response To Exercise

Heart rate and cardiac allograft vasculopathy in heart transplant recipients

2011 ◽  
Vol 30 (12) ◽  
pp. 1368-1373 ◽  
Author(s):  
Francesca Olmetti ◽  
Gian Domenico Pinna ◽  
Roberto Maestri ◽  
Andrea D'Armini ◽  
Carlo Pellegrini ◽  
...  
Keyword(s):  
Heart Rate ◽  
Heart Transplant ◽  
Cardiac Allograft Vasculopathy ◽  
Cardiac Allograft ◽  
Transplant Recipients ◽  
Allograft Vasculopathy ◽  
Heart Transplant Recipients

Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial

2016 ◽  
Vol 18 (6) ◽  
pp. 832-843 ◽  
Author(s):  
Elizabeth Sarmiento ◽  
Pablo Diez ◽  
Mauricio Arraya ◽  
Maria Jaramillo ◽  
Leticia Calahorra ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Intravenous Immunoglobulin ◽  
Heart Transplant ◽  
Transplant Recipients ◽  
Heart Transplant Recipients ◽  
Immunoglobulin Replacement
Sign in / Sign up

Export Citation Format

Share Document